What is a Paragraph IV filing for tenofovir alafenamide (TAF)?
A Paragraph IV filing is a request to market a generic drug that challenges the validity and/or the infringement of the brand’s patent(s). In the US, it happens under the Hatch-Waxman pathway (often tied to Abbreviated New Drug Application, or ANDA, submissions). The “Paragraph IV” label reflects the certification the generic applicant makes about listed patents for the reference product.
Which TAF product is being challenged when people say “tenofovir alafenamide Paragraph IV”?
“Tenofovir alafenamide” is the drug substance used in multiple brand products depending on indication (for example, HIV treatment regimens and hepatitis B treatment). A Paragraph IV filing is typically directed at a specific branded “reference drug” and the specific patents listed for that product, not just “TAF” in general. So the key question behind any “TAF Paragraph IV filing” search is usually: which brand/NDA is the generic applicant referencing.
What triggers the patent challenge and who does it involve?
A generic company files the Paragraph IV certification to assert that one or more listed patents for the reference TAF brand are invalid, unenforceable, and/or not infringed. The brand manufacturer generally responds through patent litigation if it believes the generic filing infringes its rights.
What happens after a Paragraph IV filing (timeline users usually care about)?
After the Paragraph IV ANDA is filed and accepted, the process typically moves into:
- Patent litigation initiation and a statutory stay/review period (timing can vary based on procedural events and whether other certifications are present).
- Potential design-around or settlement.
- If the generic wins or settlement allows earlier launch, the generic can enter with an effective date governed by the litigation/settlement outcome and remaining exclusivities/patents.
(Exact dates depend on the specific reference product, patent list, and court timeline.)
What do people look for when tracking “TAF Paragraph IV” news?
Searchers typically want:
- The generic applicant’s identity.
- The reference branded TAF product name and strength/formulation.
- Which patents were certified under Paragraph IV.
- Whether litigation was filed, who sued whom, and whether a settlement was reported.
- The expected launch date if the generic is approved.
How does this differ from biosimilar-style disputes or other exclusivity types?
A Paragraph IV challenge for TAF is a small-molecule generics patent dispute mechanism (ANDA/Hatch-Waxman), not a biologics/biosimilar pathway. It also targets patents listed for the reference product. Other barriers like regulatory exclusivity (for example, non-patent exclusivity or pediatric exclusivity) can still affect launch timing even if patent challenges go forward.
What risks or edge cases can change the launch outcome?
Common factors that can delay or reshape outcomes include:
- Additional patents listed later or related to formulation/use.
- Claim construction or infringement determinations in court.
- Settlements that delay entry, sometimes with “authorized generic” terms.
- Regulatory approval timing (CMC, labeling, bioequivalence) even after legal clearance.
If you want, I can pin this down to the exact filing
To identify the specific “tenofovir alafenamide Paragraph IV filing,” I need one detail: the brand product name (or the reference drug/NDA) you mean (e.g., the particular TAF-labeled product and indication). Share the product name or the generic company name and I can narrow it to the specific Paragraph IV event and what it likely implies for timelines.